#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-10	Adolescent	_
1-2	11-16	binge	_
1-3	17-25	drinking	_
1-4	26-34	disrupts	_
1-5	35-41	normal	_
1-6	42-54	trajectories	_
1-7	55-57	of	_
1-8	58-63	brain	_
1-9	64-74	functional	_
1-10	75-87	organization	_
1-11	88-91	and	_
1-12	92-103	personality	_
1-13	104-114	maturation	_
1-14	115-125	Adolescent	_
1-15	126-131	binge	_
1-16	132-140	drinking	_
1-17	141-144	has	_
1-18	145-149	been	_
1-19	150-160	associated	_
1-20	161-165	with	_
1-21	166-172	higher	_
1-22	173-178	risks	_
1-23	179-182	for	_
1-24	183-186	the	_
1-25	187-198	development	_
1-26	199-201	of	_
1-27	202-206	many	_
1-28	207-213	health	_
1-29	214-222	problems	_
1-30	223-233	throughout	_
1-31	234-237	the	_
1-32	238-246	lifespan	_
1-33	247-248	.	_

2-1	249-260	Adolescents	_
2-2	261-268	undergo	_
2-3	269-277	multiple	_
2-4	278-285	changes	_
2-5	286-290	that	_
2-6	291-298	involve	_
2-7	299-302	the	_
2-8	303-317	co-development	_
2-9	318-327	processes	_
2-10	328-330	of	_
2-11	331-336	brain	_
2-12	337-338	,	_
2-13	339-350	personality	_
2-14	351-354	and	_
2-15	355-363	behavior	_
2-16	364-365	;	_
2-17	366-375	therefore	_
2-18	376-377	,	_
2-19	378-385	certain	_
2-20	386-394	behavior	_
2-21	395-396	,	_
2-22	397-401	such	_
2-23	402-404	as	_
2-24	405-412	alcohol	_
2-25	413-424	consumption	_
2-26	425-426	,	_
2-27	427-430	can	_
2-28	431-435	have	_
2-29	436-446	disruptive	_
2-30	447-454	effects	_
2-31	455-457	on	_
2-32	458-462	both	_
2-33	463-468	brain	_
2-34	469-480	development	_
2-35	481-484	and	_
2-36	485-496	personality	_
2-37	497-507	maturation	_
2-38	508-509	.	_

3-1	510-517	However	_
3-2	518-519	,	_
3-3	520-525	these	_
3-4	526-533	effects	_
3-5	534-540	remain	_
3-6	541-548	unclear	_
3-7	549-552	due	_
3-8	553-555	to	_
3-9	556-559	the	_
3-10	560-568	scarcity	_
3-11	569-571	of	_
3-12	572-584	longitudinal	_
3-13	585-592	studies	_
3-14	593-594	.	_

4-1	595-597	In	_
4-2	598-601	the	_
4-3	602-609	current	_
4-4	610-615	study	_
4-5	616-617	,	_
4-6	618-620	we	_
4-7	621-625	used	_
4-8	626-638	multivariate	_
4-9	639-649	approaches	_
4-10	650-652	to	_
4-11	653-660	explore	_
4-12	661-675	discriminative	_
4-13	676-684	features	_
4-14	685-687	in	_
4-15	688-693	brain	_
4-16	694-704	functional	_
4-17	705-717	architecture	_
4-18	718-719	,	_
4-19	720-731	personality	_
4-20	732-738	traits	_
4-21	739-740	,	_
4-22	741-744	and	_
4-23	745-752	genetic	_
4-24	753-761	variants	_
4-25	762-764	in	_
4-26	765-776	19-year-old	_
4-27	777-788	individuals	_
4-28	789-790	(	_
4-29	791-792	n	_
4-30	793-794	=	_
4-31	795-798	212	_
4-32	799-800	)	_
4-33	801-802	.	_

5-1	803-809	Taking	_
5-2	810-819	advantage	_
5-3	820-822	of	_
5-4	823-824	a	_
5-5	825-837	longitudinal	_
5-6	838-844	design	_
5-7	845-846	,	_
5-8	847-849	we	_
5-9	850-858	selected	_
5-10	859-867	features	_
5-11	868-872	that	_
5-12	873-877	were	_
5-13	878-882	more	_
5-14	883-894	drastically	_
5-15	895-902	altered	_
5-16	903-905	in	_
5-17	906-914	drinkers	http://maven.renci.org/NeuroBridge/neurobridge#DrinkingDay
5-18	915-919	with	_
5-19	920-922	an	_
5-20	923-930	earlier	_
5-21	931-936	onset	_
5-22	937-939	of	_
5-23	940-945	binge	_
5-24	946-954	drinking	_
5-25	955-956	.	_

6-1	957-961	With	_
6-2	962-965	the	_
6-3	966-974	selected	_
6-4	975-983	features	_
6-5	984-985	,	_
6-6	986-988	we	_
6-7	989-996	trained	_
6-8	997-998	a	_
6-9	999-1011	hierarchical	_
6-10	1012-1017	model	_
6-11	1018-1020	of	_
6-12	1021-1028	support	_
6-13	1029-1035	vector	_
6-14	1036-1044	machines	_
6-15	1045-1050	using	_
6-16	1051-1052	a	_
6-17	1053-1061	training	_
6-18	1062-1068	sample	_
6-19	1069-1070	(	_
6-20	1071-1072	n	_
6-21	1073-1074	=	_
6-22	1075-1078	139	_
6-23	1079-1080	)	_
6-24	1081-1082	.	_

7-1	1083-1088	Using	_
7-2	1089-1091	an	_
7-3	1092-1103	independent	_
7-4	1104-1110	sample	_
7-5	1111-1112	(	_
7-6	1113-1114	n	_
7-7	1115-1116	=	_
7-8	1117-1119	73	_
7-9	1120-1121	)	_
7-10	1122-1123	,	_
7-11	1124-1126	we	_
7-12	1127-1133	tested	_
7-13	1134-1137	the	_
7-14	1138-1143	model	_
7-15	1144-1147	and	_
7-16	1148-1156	achieved	_
7-17	1157-1158	a	_
7-18	1159-1173	classification	_
7-19	1174-1182	accuracy	_
7-20	1183-1185	of	_
7-21	1186-1190	71.2	_
7-22	1191-1192	%	_
7-23	1193-1194	.	_

8-1	1195-1197	We	_
8-2	1198-1210	demonstrated	_
8-3	1211-1225	longitudinally	_
8-4	1226-1230	that	_
8-5	1231-1236	after	_
8-6	1237-1240	the	_
8-7	1241-1246	onset	_
8-8	1247-1249	of	_
8-9	1250-1255	binge	_
8-10	1256-1264	drinking	_
8-11	1265-1268	the	_
8-12	1269-1282	developmental	_
8-13	1283-1293	trajectory	_
8-14	1294-1296	of	_
8-15	1297-1308	improvement	_
8-16	1309-1311	in	_
8-17	1312-1323	impulsivity	_
8-18	1324-1330	slowed	_
8-19	1331-1335	down	_
8-20	1336-1337	.	_

9-1	1338-1342	This	_
9-2	1343-1348	study	_
9-3	1349-1359	identified	_
9-4	1360-1363	the	_
9-5	1364-1374	disrupting	_
9-6	1375-1382	effects	_
9-7	1383-1385	of	_
9-8	1386-1396	adolescent	_
9-9	1397-1402	binge	http://maven.renci.org/NeuroBridge/neurobridge#DrinkingBinge
9-10	1403-1411	drinking	http://maven.renci.org/NeuroBridge/neurobridge#DrinkingBinge
9-11	1412-1414	on	_
9-12	1415-1418	the	_
9-13	1419-1432	developmental	_
9-14	1433-1445	trajectories	_
9-15	1446-1448	of	_
9-16	1449-1453	both	_
9-17	1454-1459	brain	_
9-18	1460-1463	and	_
9-19	1464-1475	personality	_
9-20	1476-1477	.	_

10-1	1478-1488	Highlights	_
10-2	1489-1496	History	_
10-3	1497-1499	of	_
10-4	1500-1505	binge	_
10-5	1506-1514	drinking	_
10-6	1515-1520	could	_
10-7	1521-1523	be	_
10-8	1524-1534	identified	_
10-9	1535-1537	by	_
10-10	1538-1550	multivariate	_
10-11	1551-1559	features	_
10-12	1560-1562	at	_
10-13	1563-1566	age	_
10-14	1567-1569	19	_
10-15	1570-1571	.	_

11-1	1572-1582	Adolescent	_
11-2	1583-1588	binge	_
11-3	1589-1597	drinking	_
11-4	1598-1607	disrupted	_
11-5	1608-1615	frontal	_
11-6	1616-1628	connectivity	_
11-7	1629-1639	maturation	_
11-8	1640-1642	in	_
11-9	1643-1646	the	_
11-10	1647-1652	brain	_
11-11	1653-1654	.	_

12-1	1655-1666	Impulsivity	_
12-2	1667-1678	improvement	_
12-3	1679-1685	slowed	_
12-4	1686-1690	down	_
12-5	1691-1696	after	_
12-6	1697-1700	the	_
12-7	1701-1706	onset	_
12-8	1707-1709	of	_
12-9	1710-1720	adolescent	_
12-10	1721-1726	binge	_
12-11	1727-1735	drinking	http://maven.renci.org/NeuroBridge/neurobridge#DrinkingBinge
12-12	1736-1737	.	_

13-1	1738-1747	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
13-2	1748-1751	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
13-3	1752-1759	methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
13-4	1760-1772	Participants	_
13-5	1773-1776	The	_
13-6	1777-1783	IMAGEN	_
13-7	1784-1789	study	_
13-8	1790-1799	recruited	_
13-9	1800-1801	a	_
13-10	1802-1808	cohort	_
13-11	1809-1811	of	_
13-12	1812-1819	healthy	_
13-13	1820-1831	adolescents	_
13-14	1832-1834	at	_
13-15	1835-1838	the	_
13-16	1839-1842	age	_
13-17	1843-1845	of	_
13-18	1846-1848	14	_
13-19	1849-1850	.	_

14-1	1851-1859	Informed	_
14-2	1860-1867	consent	_
14-3	1868-1871	was	_
14-4	1872-1880	obtained	_
14-5	1881-1885	from	_
14-6	1886-1889	all	_
14-7	1890-1898	subjects	_
14-8	1899-1902	and	_
14-9	1903-1908	their	_
14-10	1909-1926	parents/guardians	_
14-11	1927-1928	.	_

15-1	1929-1932	The	_
15-2	1933-1940	genetic	_
15-3	1941-1945	data	_
15-4	1946-1950	were	_
15-5	1951-1960	collected	_
15-6	1961-1963	at	_
15-7	1964-1972	baseline	_
15-8	1973-1974	,	_
15-9	1975-1978	the	_
15-10	1979-1991	neuroimaging	_
15-11	1992-1996	data	_
15-12	1997-2001	were	_
15-13	2002-2011	collected	_
15-14	2012-2014	at	_
15-15	2015-2019	ages	_
15-16	2020-2022	14	_
15-17	2023-2026	and	_
15-18	2027-2029	19	_
15-19	2030-2031	,	_
15-20	2032-2035	and	_
15-21	2036-2049	environmental	_
15-22	2050-2053	and	_
15-23	2054-2064	behavioral	_
15-24	2065-2069	data	_
15-25	2070-2074	were	_
15-26	2075-2084	collected	_
15-27	2085-2087	at	_
15-28	2088-2092	ages	_
15-29	2093-2095	14	_
15-30	2096-2097	,	_
15-31	2098-2100	16	_
15-32	2101-2104	and	_
15-33	2105-2107	19	_
15-34	2108-2109	.	_

16-1	2110-2113	The	_
16-2	2114-2121	details	_
16-3	2122-2124	of	_
16-4	2125-2128	the	_
16-5	2129-2134	study	_
16-6	2135-2141	design	_
16-7	2142-2145	and	_
16-8	2146-2150	data	_
16-9	2151-2158	quality	_
16-10	2159-2162	are	_
16-11	2163-2172	described	_
16-12	2173-2175	in	_
16-13	2176-2177	a	_
16-14	2178-2186	previous	_
16-15	2187-2193	report	_
16-16	2194-2195	(	_
16-17	2196-2197	G	_
16-18	2198-2199	)	_
16-19	2200-2201	.	_

17-1	2202-2204	In	_
17-2	2205-2210	total	_
17-3	2211-2212	,	_
17-4	2213-2216	212	_
17-5	2217-2229	participants	_
17-6	2230-2234	were	_
17-7	2235-2243	included	_
17-8	2244-2246	in	_
17-9	2247-2250	the	_
17-10	2251-2258	current	_
17-11	2259-2264	study	_
17-12	2265-2266	;	_
17-13	2267-2268	a	_
17-14	2269-2278	flowchart	_
17-15	2279-2281	of	_
17-16	2282-2285	the	_
17-17	2286-2295	inclusion	_
17-18	2296-2305	criterion	_
17-19	2306-2308	is	_
17-20	2309-2318	presented	_
17-21	2319-2321	in	_
17-22	2322-2326	eFig	_
17-23	2327-2328	.	_

18-1	2329-2330	1	_
18-2	2331-2332	.	_

19-1	2333-2345	Measurements	_
19-2	2346-2359	Resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
19-3	2360-2370	functional	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
19-4	2371-2378	imaging	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
19-5	2379-2383	data	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
19-6	2384-2385	A	_
19-7	2386-2396	proportion	_
19-8	2397-2399	of	_
19-9	2400-2403	the	_
19-10	2404-2416	participants	_
19-11	2417-2419	in	_
19-12	2420-2423	the	_
19-13	2424-2430	IMAGEN	_
19-14	2431-2436	study	_
19-15	2437-2446	underwent	_
19-16	2447-2460	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
19-17	2461-2465	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
19-18	2466-2467	(	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
19-19	2468-2474	rsfMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
19-20	2475-2476	)	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
19-21	2477-2478	.	_

20-1	2479-2481	In	_
20-2	2482-2485	the	_
20-3	2486-2492	IMAGEN	_
20-4	2493-2498	study	_
20-5	2499-2500	,	_
20-6	2501-2505	much	_
20-7	2506-2510	less	_
20-8	2511-2517	rsfMRI	_
20-9	2518-2522	data	_
20-10	2523-2524	(	_
20-11	2525-2526	n	_
20-12	2527-2528	=	_
20-13	2529-2532	389	_
20-14	2533-2534	)	_
20-15	2535-2539	were	_
20-16	2540-2549	collected	_
20-17	2550-2552	at	_
20-18	2553-2556	the	_
20-19	2557-2561	base	_
20-20	2562-2566	line	_
20-21	2567-2568	(	_
20-22	2569-2572	i.e	_
20-23	2573-2574	.	_

21-1	2575-2578	age	_
21-2	2579-2581	14	_
21-3	2582-2583	)	_
21-4	2584-2585	.	_

22-1	2586-2588	As	_
22-2	2589-2595	rsfMRI	_
22-3	2596-2599	got	_
22-4	2600-2604	more	_
22-5	2605-2608	and	_
22-6	2609-2613	more	_
22-7	2614-2623	attention	_
22-8	2624-2625	,	_
22-9	2626-2630	more	_
22-10	2631-2635	data	_
22-11	2636-2637	(	_
22-12	2638-2639	n	_
22-13	2640-2641	=	_
22-14	2642-2646	1069	_
22-15	2647-2648	)	_
22-16	2649-2653	were	_
22-17	2654-2663	collected	_
22-18	2664-2666	at	_
22-19	2667-2670	the	_
22-20	2671-2680	follow-up	_
22-21	2681-2686	stage	_
22-22	2687-2688	(	_
22-23	2689-2692	i.e	_
22-24	2693-2694	.	_

23-1	2695-2698	age	_
23-2	2699-2701	19	_
23-3	2702-2703	)	_
23-4	2704-2705	.	_

24-1	2706-2709	All	_
24-2	2710-2714	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
24-3	2715-2719	data	_
24-4	2720-2724	were	_
24-5	2725-2737	preprocessed	_
24-6	2738-2740	by	_
24-7	2741-2744	the	_
24-8	2745-2749	Data	_
24-9	2750-2760	Processing	_
24-10	2761-2770	Assistant	_
24-11	2771-2774	for	_
24-12	2775-2782	Resting	_
24-13	2783-2788	State	_
24-14	2789-2793	fMRI	_
24-15	2794-2795	(	_
24-16	2796-2812	rfmri.org/DPARSF	_
24-17	2813-2814	)	_
24-18	2815-2816	.	_

25-1	2817-2820	For	_
25-2	2821-2825	each	_
25-3	2826-2836	individual	_
25-4	2837-2838	,	_
25-5	2839-2841	we	_
25-6	2842-2852	calculated	_
25-7	2853-2856	the	_
25-8	2857-2870	resting-state	_
25-9	2871-2881	functional	_
25-10	2882-2894	connectivity	_
25-11	2895-2896	(	_
25-12	2897-2901	rsFC	_
25-13	2902-2903	)	_
25-14	2904-2911	between	_
25-15	2912-2916	each	_
25-16	2917-2921	pair	_
25-17	2922-2924	of	_
25-18	2925-2930	brain	_
25-19	2931-2938	regions	_
25-20	2939-2940	[	_
25-21	2941-2947	19,900	_
25-22	2948-2953	links	_
25-23	2954-2957	for	_
25-24	2958-2961	200	_
25-25	2962-2975	atlas-defined	_
25-26	2976-2981	brain	_
25-27	2982-2989	regions	_
25-28	2990-2991	,	_
25-29	2992-3000	Craddock	_
25-30	3001-3005	2011	_
25-31	3006-3011	Atlas	_
25-32	3012-3018	eTable	_
25-33	3019-3020	3	_
25-34	3021-3022	]	_
25-35	3023-3024	.	_

26-1	3025-3036	Genome-wide	_
26-2	3037-3045	genotype	_
26-3	3046-3050	data	_
26-4	3051-3058	Details	_
26-5	3059-3061	of	_
26-6	3062-3069	genetic	_
26-7	3070-3074	data	_
26-8	3075-3079	have	_
26-9	3080-3084	been	_
26-10	3085-3093	reported	_
26-11	3094-3104	previously	_
26-12	3105-3106	;	_
26-13	3107-3109	we	_
26-14	3110-3114	have	_
26-15	3115-3123	included	_
26-16	3124-3132	detailed	_
26-17	3133-3145	descriptions	_
26-18	3146-3148	in	_
26-19	3149-3152	the	_
26-20	3153-3161	eMethods	_
26-21	3162-3163	.	_

27-1	3164-3171	Briefly	_
27-2	3172-3173	,	_
27-3	3174-3176	we	_
27-4	3177-3186	converted	_
27-5	3187-3190	all	_
27-6	3191-3197	single	_
27-7	3198-3208	nucleotide	_
27-8	3209-3222	polymorphisms	_
27-9	3223-3224	(	_
27-10	3225-3228	SNP	_
27-11	3229-3230	)	_
27-12	3231-3235	into	_
27-13	3236-3242	binary	_
27-14	3243-3252	variables	_
27-15	3253-3254	;	_
27-16	3255-3257	no	_
27-17	3258-3267	mutations	_
27-18	3268-3272	were	_
27-19	3273-3281	assigned	_
27-20	3282-3285	the	_
27-21	3286-3292	number	_
27-22	3293-3294	“	_
27-23	3295-3299	zero	_
27-24	3300-3301	”	_
27-25	3302-3305	and	_
27-26	3306-3315	mutations	_
27-27	3316-3320	were	_
27-28	3321-3329	assigned	_
27-29	3330-3333	the	_
27-30	3334-3340	number	_
27-31	3341-3342	“	_
27-32	3343-3346	one	_
27-33	3347-3348	”	_
27-34	3349-3350	.	_

28-1	3351-3360	Substance	_
28-2	3361-3364	use	_
28-3	3365-3367	We	_
28-4	3368-3372	used	_
28-5	3373-3376	the	_
28-6	3377-3385	European	_
28-7	3386-3392	School	_
28-8	3393-3399	Survey	_
28-9	3400-3407	Project	_
28-10	3408-3410	on	_
28-11	3411-3418	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
28-12	3419-3422	and	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
28-13	3423-3428	Drugs	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
28-14	3429-3430	[	_
28-15	3431-3436	ESPAD	_
28-16	3437-3438	(	_
28-17	3439-3441	G.	_
28-18	3442-3443	)	_
28-19	3444-3445	]	_
28-20	3446-3449	for	_
28-21	3450-3454	ages	_
28-22	3455-3457	14	_
28-23	3458-3459	,	_
28-24	3460-3462	16	_
28-25	3463-3464	,	_
28-26	3465-3468	and	_
28-27	3469-3471	19	_
28-28	3472-3477	years	_
28-29	3478-3480	to	_
28-30	3481-3487	assess	_
28-31	3488-3491	the	_
28-32	3492-3499	alcohol	_
28-33	3500-3511	consumption	_
28-34	3512-3513	,	_
28-35	3514-3521	smoking	_
28-36	3522-3523	,	_
28-37	3524-3527	and	_
28-38	3528-3536	cannabis	_
28-39	3537-3540	use	_
28-40	3541-3542	.	_

29-1	3543-3546	The	_
29-2	3547-3552	ESPAD	_
29-3	3553-3561	category	_
29-4	3562-3568	scores	_
29-5	3569-3572	are	_
29-6	3573-3575	as	_
29-7	3576-3583	follows	_
29-8	3584-3585	:	_
29-9	3586-3587	0	_
29-10	3588-3589	(	_
29-11	3590-3591	0	_
29-12	3592-3593	)	_
29-13	3594-3595	,	_
29-14	3596-3597	1	_
29-15	3598-3599	(	_
29-16	3600-3603	1–2	_
29-17	3604-3605	)	_
29-18	3606-3607	,	_
29-19	3608-3609	2	_
29-20	3610-3611	(	_
29-21	3612-3615	3–5	_
29-22	3616-3617	)	_
29-23	3618-3619	,	_
29-24	3620-3621	3	_
29-25	3622-3623	(	_
29-26	3624-3627	6–9	_
29-27	3628-3629	)	_
29-28	3630-3631	,	_
29-29	3632-3633	4	_
29-30	3634-3635	(	_
29-31	3636-3641	10–19	_
29-32	3642-3643	)	_
29-33	3644-3645	,	_
29-34	3646-3647	5	_
29-35	3648-3649	(	_
29-36	3650-3655	20–39	_
29-37	3656-3657	)	_
29-38	3658-3659	,	_
29-39	3660-3661	6	_
29-40	3662-3663	(	_
29-41	3664-3667	≥40	_
29-42	3668-3669	)	_
29-43	3670-3671	.	_

30-1	3672-3675	The	_
30-2	3676-3683	primary	_
30-3	3684-3693	questions	_
30-4	3694-3696	of	_
30-5	3697-3705	interest	_
30-6	3706-3715	concerned	_
30-7	3716-3724	lifetime	_
30-8	3725-3732	alcohol	_
30-9	3733-3736	use	_
30-10	3737-3738	[	_
30-11	3739-3742	for	_
30-12	3743-3750	example	_
30-13	3751-3752	,	_
30-14	3753-3755	On	_
30-15	3756-3759	how	_
30-16	3760-3764	many	_
30-17	3765-3774	occasions	_
30-18	3775-3776	(	_
30-19	3777-3779	if	_
30-20	3780-3783	any	_
30-21	3784-3785	)	_
30-22	3786-3788	in	_
30-23	3789-3793	your	_
30-24	3794-3802	lifetime	_
30-25	3803-3807	have	_
30-26	3808-3811	you	_
30-27	3812-3815	had	_
30-28	3816-3819	any	_
30-29	3820-3829	alcoholic	_
30-30	3830-3838	beverage	_
30-31	3839-3840	?	_

31-1	3841-3842	]	_
31-2	3843-3844	;	_
31-3	3845-3853	lifetime	_
31-4	3854-3861	drunken	_
31-5	3862-3870	episodes	_
31-6	3871-3872	[	_
31-7	3873-3876	for	_
31-8	3877-3884	example	_
31-9	3885-3886	,	_
31-10	3887-3889	On	_
31-11	3890-3893	how	_
31-12	3894-3898	many	_
31-13	3899-3908	occasions	_
31-14	3909-3910	(	_
31-15	3911-3913	if	_
31-16	3914-3917	any	_
31-17	3918-3919	)	_
31-18	3920-3922	in	_
31-19	3923-3927	your	_
31-20	3928-3936	lifetime	_
31-21	3937-3941	have	_
31-22	3942-3945	you	_
31-23	3946-3950	been	_
31-24	3951-3956	drunk	_
31-25	3957-3961	from	_
31-26	3962-3970	drinking	_
31-27	3971-3980	alcoholic	_
31-28	3981-3990	beverages	_
31-29	3991-3992	?	_

32-1	3993-3994	]	_
32-2	3995-3996	;	_
32-3	3997-4005	lifetime	_
32-4	4006-4013	smoking	_
32-5	4014-4015	(	_
32-6	4016-4019	for	_
32-7	4020-4027	example	_
32-8	4028-4029	,	_
32-9	4030-4032	On	_
32-10	4033-4036	how	_
32-11	4037-4041	many	_
32-12	4042-4051	occasions	_
32-13	4052-4058	during	_
32-14	4059-4063	your	_
32-15	4064-4072	lifetime	_
32-16	4073-4077	have	_
32-17	4078-4081	you	_
32-18	4082-4088	smoked	_
32-19	4089-4099	cigarettes	_
32-20	4100-4101	?	_

33-1	4102-4103	)	_
33-2	4104-4105	;	_
33-3	4106-4109	and	_
33-4	4110-4118	lifetime	_
33-5	4119-4127	cannabis	_
33-6	4128-4131	use	_
33-7	4132-4133	(	_
33-8	4134-4137	for	_
33-9	4138-4145	example	_
33-10	4146-4147	,	_
33-11	4148-4150	On	_
33-12	4151-4154	how	_
33-13	4155-4159	many	_
33-14	4160-4169	occasions	_
33-15	4170-4172	in	_
33-16	4173-4177	your	_
33-17	4178-4183	whole	_
33-18	4184-4192	lifetime	_
33-19	4193-4197	have	_
33-20	4198-4201	you	_
33-21	4202-4206	used	_
33-22	4207-4216	marijuana	_
33-23	4217-4219	or	_
33-24	4220-4227	hashish	_
33-25	4228-4229	?	_
33-26	4230-4231	)	_
33-27	4232-4233	.	_

34-1	4234-4243	Variables	_
34-2	4244-4254	associated	_
34-3	4255-4259	with	_
34-4	4260-4263	the	_
34-5	4264-4273	occasions	_
34-6	4274-4276	of	_
34-7	4277-4284	alcohol	_
34-8	4285-4288	use	_
34-9	4289-4292	and	_
34-10	4293-4296	the	_
34-11	4297-4305	episodes	_
34-12	4306-4308	of	_
34-13	4309-4314	binge	_
34-14	4315-4323	drinking	_
34-15	4324-4328	were	_
34-16	4329-4337	measured	_
34-17	4338-4340	at	_
34-18	4341-4346	three	_
34-19	4347-4351	time	_
34-20	4352-4358	points	_
34-21	4359-4360	(	_
34-22	4361-4365	ages	_
34-23	4366-4368	14	_
34-24	4369-4370	,	_
34-25	4371-4373	16	_
34-26	4374-4375	,	_
34-27	4376-4379	and	_
34-28	4380-4382	19	_
34-29	4383-4384	)	_
34-30	4385-4386	,	_
34-31	4387-4390	and	_
34-32	4391-4394	the	_
34-33	4395-4399	data	_
34-34	4400-4404	were	_
34-35	4405-4414	organized	_
34-36	4415-4424	according	_
34-37	4425-4427	to	_
34-38	4428-4431	the	_
34-39	4432-4440	duration	_
34-40	4441-4444	and	_
34-41	4445-4451	amount	_
34-42	4452-4454	of	_
34-43	4455-4460	binge	_
34-44	4461-4469	drinking	_
34-45	4470-4476	during	_
34-46	4477-4488	adolescence	_
34-47	4489-4490	(	_
34-48	4491-4494	Fig	_
34-49	4495-4496	.	_

35-1	4497-4498	1	_
35-2	4499-4500	,	_
35-3	4501-4505	eFig	_
35-4	4506-4507	.	_

36-1	4508-4509	1	_
36-2	4510-4511	)	_
36-3	4512-4513	.	_

37-1	4514-4518	More	_
37-2	4519-4526	details	_
37-3	4527-4530	are	_
37-4	4531-4539	provided	_
37-5	4540-4542	in	_
37-6	4543-4546	the	_
37-7	4547-4555	eMethods	_
37-8	4556-4557	.	_

38-1	4558-4567	Cognition	_
38-2	4568-4571	and	http://maven.renci.org/NeuroBridge/neurobridge#PhysicalMeasurement
38-3	4572-4583	personality	_
38-4	4584-4586	We	_
38-5	4587-4591	used	_
38-6	4592-4595	the	_
38-7	4596-4605	Cambridge	http://maven.renci.org/NeuroBridge/neurobridge#CambridgeNeuropsychologicalTestAutomatedBattery
38-8	4606-4624	Neuropsychological	http://maven.renci.org/NeuroBridge/neurobridge#CambridgeNeuropsychologicalTestAutomatedBattery
38-9	4625-4629	Test	http://maven.renci.org/NeuroBridge/neurobridge#CambridgeNeuropsychologicalTestAutomatedBattery
38-10	4630-4639	Automated	http://maven.renci.org/NeuroBridge/neurobridge#CambridgeNeuropsychologicalTestAutomatedBattery
38-11	4640-4647	Battery	http://maven.renci.org/NeuroBridge/neurobridge#CambridgeNeuropsychologicalTestAutomatedBattery
38-12	4648-4649	[	http://maven.renci.org/NeuroBridge/neurobridge#CambridgeNeuropsychologicalTestAutomatedBattery
38-13	4650-4656	Cantab	http://maven.renci.org/NeuroBridge/neurobridge#CambridgeNeuropsychologicalTestAutomatedBattery
38-14	4657-4658	]	_
38-15	4659-4660	,	_
38-16	4661-4676	Monetary-Choice	http://maven.renci.org/NeuroBridge/neurobridge#Questionnaire
38-17	4677-4690	Questionnaire	http://maven.renci.org/NeuroBridge/neurobridge#Questionnaire
38-18	4691-4692	(	http://maven.renci.org/NeuroBridge/neurobridge#Questionnaire
38-19	4693-4698	KIRBY	http://maven.renci.org/NeuroBridge/neurobridge#Questionnaire
38-20	4699-4703	rate	http://maven.renci.org/NeuroBridge/neurobridge#Questionnaire
38-21	4704-4705	)	http://maven.renci.org/NeuroBridge/neurobridge#Questionnaire
38-22	4706-4707	,	_
38-23	4708-4719	personality	_
38-24	4720-4735	characteristics	_
38-25	4736-4741	tests	_
38-26	4742-4743	,	_
38-27	4744-4753	including	_
38-28	4754-4757	the	_
38-29	4758-4765	Revised	_
38-30	4766-4769	NEO	_
38-31	4770-4781	Personality	http://maven.renci.org/NeuroBridge/neurobridge#NEOPersonalityInventoryRevised
38-32	4782-4791	Inventory	http://maven.renci.org/NeuroBridge/neurobridge#NEOPersonalityInventoryRevised
38-33	4792-4793	[	http://maven.renci.org/NeuroBridge/neurobridge#NEOPersonalityInventoryRevised
38-34	4794-4802	NEO-PI-R	http://maven.renci.org/NeuroBridge/neurobridge#NEOPersonalityInventoryRevised
38-35	4803-4804	]	_
38-36	4805-4806	,	_
38-37	4807-4810	and	_
38-38	4811-4814	the	_
38-39	4815-4824	Substance	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale
38-40	4825-4828	Use	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale
38-41	4829-4833	Risk	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale
38-42	4834-4841	Profile	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale
38-43	4842-4847	Scale	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale
38-44	4848-4849	[	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale
38-45	4850-4855	SURPS	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale
38-46	4856-4857	]	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale
38-47	4858-4860	to	_
38-48	4861-4867	assess	_
38-49	4868-4877	cognition	_
38-50	4878-4881	and	_
38-51	4882-4893	personality	_
38-52	4894-4901	factors	_
38-53	4902-4903	.	_

39-1	4904-4911	Further	_
39-2	4912-4919	details	_
39-3	4920-4923	are	_
39-4	4924-4932	provided	_
39-5	4933-4935	in	_
39-6	4936-4939	the	_
39-7	4940-4948	eMethods	_
39-8	4949-4950	.	_

40-1	4951-4962	Statistical	_
40-2	4963-4971	analyses	_
40-3	4972-4982	Univariate	_
40-4	4983-4991	approach	_
40-5	4992-4994	We	_
40-6	4995-4999	used	_
40-7	5000-5010	two-sample	_
40-8	5011-5018	Student	_
40-9	5019-5021	's	_
40-10	5022-5029	t-tests	_
40-11	5030-5031	,	_
40-12	5032-5043	controlling	_
40-13	5044-5047	for	_
40-14	5048-5058	covariates	_
40-15	5059-5060	(	_
40-16	5061-5064	sex	_
40-17	5065-5068	and	_
40-18	5069-5073	site	_
40-19	5074-5075	)	_
40-20	5076-5079	for	_
40-21	5080-5090	univariate	_
40-22	5091-5099	analyses	_
40-23	5100-5101	,	_
40-24	5102-5105	and	_
40-25	5106-5114	employed	_
40-26	5115-5116	a	_
40-27	5117-5122	false	_
40-28	5123-5132	discovery	_
40-29	5133-5137	rate	_
40-30	5138-5139	(	_
40-31	5140-5143	FDR	_
40-32	5144-5145	)	_
40-33	5146-5156	correction	_
40-34	5157-5160	for	_
40-35	5161-5169	multiple	_
40-36	5170-5181	comparisons	_
40-37	5182-5183	.	_

41-1	5184-5196	Multivariate	_
41-2	5197-5205	approach	_
41-3	5206-5210	with	_
41-4	5211-5228	hypothesis-guided	_
41-5	5229-5236	feature	_
41-6	5237-5246	selection	_
41-7	5247-5249	To	_
41-8	5250-5258	identify	_
41-9	5259-5273	discriminative	_
41-10	5274-5282	features	_
41-11	5283-5285	in	_
41-12	5286-5290	high	_
41-13	5291-5302	dimensional	_
41-14	5303-5308	space	_
41-15	5309-5312	and	_
41-16	5313-5320	control	_
41-17	5321-5324	for	_
41-18	5325-5328	the	_
41-19	5329-5341	over-fitting	_
41-20	5342-5349	problem	_
41-21	5350-5351	,	_
41-22	5352-5354	we	_
41-23	5355-5363	combined	_
41-24	5364-5371	several	_
41-25	5372-5381	dimension	_
41-26	5382-5391	reduction	_
41-27	5392-5402	approaches	_
41-28	5403-5407	with	_
41-29	5408-5411	the	_
41-30	5412-5424	multivariate	_
41-31	5425-5432	pattern	_
41-32	5433-5441	analysis	_
41-33	5442-5450	approach	_
41-34	5451-5452	[	_
41-35	5453-5467	Support-Vector	_
41-36	5468-5475	Machine	_
41-37	5476-5477	(	_
41-38	5478-5481	SVM	_
41-39	5482-5483	)	_
41-40	5484-5485	,	_
41-41	5486-5487	]	_
41-42	5488-5489	.	_

42-1	5490-5493	The	_
42-2	5494-5498	main	_
42-3	5499-5504	steps	_
42-4	5505-5508	are	_
42-5	5509-5518	described	_
42-6	5519-5524	below	_
42-7	5525-5528	and	_
42-8	5529-5539	additional	_
42-9	5540-5547	details	_
42-10	5548-5551	are	_
42-11	5552-5560	provided	_
42-12	5561-5563	in	_
42-13	5564-5567	the	_
42-14	5568-5576	eMethods	_
42-15	5577-5578	.	_

43-1	5579-5588	Candidate	_
43-2	5589-5596	feature	_
43-3	5597-5606	selection	_
43-4	5607-5610	and	_
43-5	5611-5620	dimension	_
43-6	5621-5630	reduction	_
43-7	5631-5633	To	_
43-8	5634-5640	reduce	_
43-9	5641-5655	dimensionality	_
43-10	5656-5657	,	_
43-11	5658-5660	we	_
43-12	5661-5666	first	_
43-13	5667-5671	used	_
43-14	5672-5675	the	_
43-15	5676-5693	lasso-regularized	_
43-16	5694-5702	logistic	_
43-17	5703-5713	regression	_
43-18	5714-5716	to	_
43-19	5717-5723	select	_
43-20	5724-5727	the	_
43-21	5728-5732	most	_
43-22	5733-5747	discriminative	_
43-23	5748-5753	rsFCs	_
43-24	5754-5761	between	_
43-25	5762-5765	the	_
43-26	5766-5771	binge	_
43-27	5772-5780	drinkers	_
43-28	5781-5784	and	_
43-29	5785-5797	non-drinking	_
43-30	5798-5806	controls	_
43-31	5807-5808	.	_

44-1	5809-5820	Chi-squared	_
44-2	5821-5826	tests	_
44-3	5827-5831	were	_
44-4	5832-5836	used	_
44-5	5837-5839	to	_
44-6	5840-5846	select	_
44-7	5847-5850	the	_
44-8	5851-5855	SNPs	_
44-9	5856-5860	with	_
44-10	5861-5874	significantly	_
44-11	5875-5884	different	_
44-12	5885-5896	frequencies	_
44-13	5897-5899	in	_
44-14	5900-5908	subjects	_
44-15	5909-5913	with	_
44-16	5914-5915	a	_
44-17	5916-5923	history	_
44-18	5924-5926	of	_
44-19	5927-5932	binge	_
44-20	5933-5941	drinking	_
44-21	5942-5950	compared	_
44-22	5951-5953	to	_
44-23	5954-5959	those	_
44-24	5960-5967	without	_
44-25	5968-5969	a	_
44-26	5970-5975	binge	_
44-27	5976-5984	drinking	_
44-28	5985-5992	history	_
44-29	5993-5994	.	_

45-1	5995-5999	Next	_
45-2	6000-6001	,	_
45-3	6002-6009	instead	_
45-4	6010-6012	of	_
45-5	6013-6018	using	_
45-6	6019-6024	these	_
45-7	6025-6033	features	_
45-8	6034-6036	as	_
45-9	6037-6043	inputs	_
45-10	6044-6046	to	_
45-11	6047-6050	the	_
45-12	6051-6054	SVM	_
45-13	6055-6056	,	_
45-14	6057-6059	we	_
45-15	6060-6067	further	_
45-16	6068-6075	reduced	_
45-17	6076-6079	the	_
45-18	6080-6094	dimensionality	_
45-19	6095-6097	by	_
45-20	6098-6109	calculating	_
45-21	6110-6114	four	_
45-22	6115-6122	summary	_
45-23	6123-6129	scores	_
45-24	6130-6131	,	_
45-25	6132-6141	including	_
45-26	6142-6161	increased/decreased	_
45-27	6162-6166	rsFC	_
45-28	6167-6168	(	_
45-29	6169-6176	iFC/dFC	_
45-30	6177-6178	)	_
45-31	6179-6181	or	_
45-32	6182-6197	risk/protective	_
45-33	6198-6201	SNP	_
45-34	6202-6203	(	_
45-35	6204-6213	rSNP/pSNP	_
45-36	6214-6215	)	_
45-37	6216-6222	scores	_
45-38	6223-6224	(	_
45-39	6225-6228	Fig	_
45-40	6229-6230	.	_

46-1	6231-6233	2A	_
46-2	6234-6235	)	_
46-3	6236-6237	.	_

47-1	6238-6240	To	_
47-2	6241-6248	prevent	_
47-3	6249-6254	model	_
47-4	6255-6267	over-fitting	_
47-5	6268-6270	in	_
47-6	6271-6274	the	_
47-7	6275-6283	training	_
47-8	6284-6290	sample	_
47-9	6291-6292	,	_
47-10	6293-6295	we	_
47-11	6296-6303	applied	_
47-12	6304-6307	the	_
47-13	6308-6321	leave-one-out	_
47-14	6322-6323	(	_
47-15	6324-6327	LOO	_
47-16	6328-6329	)	_
47-17	6330-6346	cross-validation	_
47-18	6347-6356	procedure	_
47-19	6357-6359	to	_
47-20	6360-6363	the	_
47-21	6364-6367	SVM	_
47-22	6368-6369	,	_
47-23	6370-6375	which	_
47-24	6376-6379	was	_
47-25	6380-6385	built	_
47-26	6386-6388	by	_
47-27	6389-6392	the	_
47-28	6393-6396	two	_
47-29	6397-6402	steps	_
47-30	6403-6412	described	_
47-31	6413-6418	above	_
47-32	6419-6420	.	_

48-1	6421-6425	Only	_
48-2	6426-6431	those	_
48-3	6432-6440	features	_
48-4	6441-6442	(	_
48-5	6443-6447	rsFC	_
48-6	6448-6451	and	_
48-7	6452-6455	SNP	_
48-8	6456-6457	)	_
48-9	6458-6462	that	_
48-10	6463-6467	were	_
48-11	6468-6478	repeatedly	_
48-12	6479-6487	selected	_
48-13	6488-6490	in	_
48-14	6491-6492	>	_
48-15	6493-6495	90	_
48-16	6496-6497	%	_
48-17	6498-6500	of	_
48-18	6501-6511	iterations	_
48-19	6512-6518	during	_
48-20	6519-6522	the	_
48-21	6523-6526	LOO	_
48-22	6527-6531	were	_
48-23	6532-6542	considered	_
48-24	6543-6551	robustly	_
48-25	6552-6566	discriminating	_
48-26	6567-6575	features	_
48-27	6576-6577	(	_
48-28	6578-6584	namely	_
48-29	6585-6586	,	_
48-30	6587-6590	the	_
48-31	6591-6600	candidate	_
48-32	6601-6609	features	_
48-33	6610-6611	)	_
48-34	6612-6619	between	_
48-35	6620-6623	the	_
48-36	6624-6629	binge	_
48-37	6630-6638	drinkers	_
48-38	6639-6642	and	_
48-39	6643-6646	the	_
48-40	6647-6654	control	_
48-41	6655-6663	subjects	_
48-42	6664-6665	.	_

49-1	6666-6668	We	_
49-2	6669-6676	trained	_
49-3	6677-6680	one	_
49-4	6681-6684	SVM	_
49-5	6685-6688	for	_
49-6	6689-6692	the	_
49-7	6693-6702	long-term	_
49-8	6703-6711	drinkers	_
49-9	6712-6713	(	_
49-10	6714-6722	SVM-long	_
49-11	6723-6733	classifier	_
49-12	6734-6735	)	_
49-13	6736-6739	and	_
49-14	6740-6743	the	_
49-15	6744-6749	other	_
49-16	6750-6753	SVM	_
49-17	6754-6757	for	_
49-18	6758-6761	the	_
49-19	6762-6772	short-term	_
49-20	6773-6781	drinkers	_
49-21	6782-6783	(	_
49-22	6784-6793	SVM-short	_
49-23	6794-6804	classifier	_
49-24	6805-6806	)	_
49-25	6807-6808	.	_

50-1	6809-6811	To	_
50-2	6812-6818	assess	_
50-3	6819-6822	the	_
50-4	6823-6835	contribution	_
50-5	6836-6838	of	_
50-6	6839-6843	each	_
50-7	6844-6850	domain	_
50-8	6851-6852	(	_
50-9	6853-6856	SNP	_
50-10	6857-6858	,	_
50-11	6859-6863	rsFC	_
50-12	6864-6865	,	_
50-13	6866-6869	and	_
50-14	6870-6880	covariates	_
50-15	6881-6882	)	_
50-16	6883-6885	in	_
50-17	6886-6900	classification	_
50-18	6901-6902	,	_
50-19	6903-6905	we	_
50-20	6906-6914	compared	_
50-21	6915-6918	the	_
50-22	6919-6924	model	_
50-23	6925-6936	performance	_
50-24	6937-6943	before	_
50-25	6944-6947	and	_
50-26	6948-6953	after	_
50-27	6954-6957	the	_
50-28	6958-6965	removal	_
50-29	6966-6968	of	_
50-30	6969-6973	each	_
50-31	6974-6980	domain	_
50-32	6981-6985	from	_
50-33	6986-6989	the	_
50-34	6990-6995	model	_
50-35	6996-7002	inputs	_
50-36	7003-7004	.	_

51-1	7005-7008	The	_
51-2	7009-7018	candidate	_
51-3	7019-7027	features	_
51-4	7028-7030	in	_
51-5	7031-7034	the	_
51-6	7035-7042	domains	_
51-7	7043-7056	significantly	_
51-8	7057-7068	contributed	_
51-9	7069-7071	to	_
51-10	7072-7080	SVM-long	_
51-11	7081-7084	and	_
51-12	7085-7094	SVM-short	_
51-13	7095-7099	were	_
51-14	7100-7110	summarized	_
51-15	7111-7115	into	_
51-16	7116-7120	four	_
51-17	7121-7124	new	_
51-18	7125-7131	scores	_
51-19	7132-7133	(	_
51-20	7134-7137	iFC	_
51-21	7138-7139	,	_
51-22	7140-7143	dFC	_
51-23	7144-7145	,	_
51-24	7146-7150	rSNP	_
51-25	7151-7152	,	_
51-26	7153-7156	and	_
51-27	7157-7161	pSNP	_
51-28	7162-7163	)	_
51-29	7164-7167	for	_
51-30	7168-7172	next	_
51-31	7173-7178	stage	_
51-32	7179-7180	.	_

52-1	7181-7198	Hypothesis-guided	_
52-2	7199-7206	feature	_
52-3	7207-7216	selection	_
52-4	7217-7226	According	_
52-5	7227-7229	to	_
52-6	7230-7233	our	_
52-7	7234-7244	hypothesis	_
52-8	7245-7247	of	_
52-9	7248-7253	trend	_
52-10	7254-7257	for	_
52-11	7258-7261	the	_
52-12	7262-7274	consequences	_
52-13	7275-7277	of	_
52-14	7278-7288	adolescent	_
52-15	7289-7294	binge	_
52-16	7295-7303	drinking	_
52-17	7304-7305	,	_
52-18	7306-7308	we	_
52-19	7309-7316	focused	_
52-20	7317-7319	on	_
52-21	7320-7323	the	_
52-22	7324-7335	personality	_
52-23	7336-7342	scores	_
52-24	7343-7346	and	_
52-25	7347-7350	the	_
52-26	7351-7355	four	_
52-27	7356-7359	new	_
52-28	7360-7366	scores	_
52-29	7367-7378	established	_
52-30	7379-7381	by	_
52-31	7382-7391	candidate	_
52-32	7392-7400	features	_
52-33	7401-7402	.	_

53-1	7403-7405	We	_
53-2	7406-7414	employed	_
53-3	7415-7418	the	_
53-4	7419-7438	Jonckheere-Terpstra	_
53-5	7439-7444	trend	_
53-6	7445-7449	test	_
53-7	7450-7452	to	_
53-8	7453-7461	identify	_
53-9	7462-7465	the	_
53-10	7466-7474	features	_
53-11	7475-7479	that	_
53-12	7480-7484	were	_
53-13	7485-7495	consistent	_
53-14	7496-7500	with	_
53-15	7501-7504	the	_
53-16	7505-7515	hypothesis	_
53-17	7516-7518	of	_
53-18	7519-7524	trend	_
53-19	7525-7526	(	_
53-20	7527-7530	i.e	_
53-21	7531-7532	.	_

54-1	7533-7536	the	_
54-2	7537-7551	discriminative	_
54-3	7552-7560	features	_
54-4	7561-7567	having	_
54-5	7568-7571	the	_
54-6	7572-7579	largest	_
54-7	7580-7581	,	_
54-8	7582-7594	intermediate	_
54-9	7595-7598	and	_
54-10	7599-7607	smallest	_
54-11	7608-7618	deviations	_
54-12	7619-7623	from	_
54-13	7624-7627	the	_
54-14	7628-7635	control	_
54-15	7636-7641	group	_
54-16	7642-7644	in	_
54-17	7645-7648	the	_
54-18	7649-7654	binge	_
54-19	7655-7663	drinkers	_
54-20	7664-7668	with	_
54-21	7669-7672	the	_
54-22	7673-7680	longest	_
54-23	7681-7682	,	_
54-24	7683-7689	medium	_
54-25	7690-7691	,	_
54-26	7692-7695	and	_
54-27	7696-7704	shortest	_
54-28	7705-7712	history	_
54-29	7713-7715	of	_
54-30	7716-7721	binge	_
54-31	7722-7730	drinking	_
54-32	7731-7732	,	_
54-33	7733-7745	respectively	_
54-34	7746-7747	;	_
54-35	7748-7751	Fig	_
54-36	7752-7753	.	_

55-1	7754-7756	3A	_
55-2	7757-7758	,	_
55-3	7759-7760	B	_
55-4	7761-7762	,	_
55-5	7763-7766	and	_
55-6	7767-7768	C	_
55-7	7769-7770	)	_
55-8	7771-7772	.	_

56-1	7773-7785	Hierarchical	_
56-2	7786-7796	classifier	_
56-3	7797-7804	Finally	_
56-4	7805-7806	,	_
56-5	7807-7809	we	_
56-6	7810-7815	built	_
56-7	7816-7817	a	_
56-8	7818-7830	hierarchical	_
56-9	7831-7841	classifier	_
56-10	7842-7843	,	_
56-11	7844-7849	which	_
56-12	7850-7859	consisted	_
56-13	7860-7862	of	_
56-14	7863-7866	two	_
56-15	7867-7873	layers	_
56-16	7874-7875	:	_
56-17	7876-7879	the	_
56-18	7880-7888	in-layer	_
56-19	7889-7892	and	_
56-20	7893-7896	the	_
56-21	7897-7906	out-layer	_
56-22	7907-7908	(	_
56-23	7909-7912	Fig	_
56-24	7913-7914	.	_

57-1	7915-7917	3D	_
57-2	7918-7919	)	_
57-3	7920-7921	.	_

58-1	7922-7924	To	_
58-2	7925-7932	further	_
58-3	7933-7939	reduce	_
58-4	7940-7954	dimensionality	_
58-5	7955-7956	,	_
58-6	7957-7959	we	_
58-7	7960-7971	constructed	_
58-8	7972-7975	the	_
58-9	7976-7984	in-layer	_
58-10	7985-7989	with	_
58-11	7990-7995	three	_
58-12	7996-8000	SVMs	_
58-13	8001-8007	taking	_
58-14	8008-8011	the	_
58-15	8012-8018	inputs	_
58-16	8019-8023	from	_
58-17	8024-8034	covariates	_
58-18	8035-8036	(	_
58-19	8037-8041	SVM1	_
58-20	8042-8043	)	_
58-21	8044-8045	,	_
58-22	8046-8050	rsFC	_
58-23	8051-8054	and	_
58-24	8055-8058	SNP	_
58-25	8059-8060	(	_
58-26	8061-8065	SVM2	_
58-27	8066-8067	)	_
58-28	8068-8069	,	_
58-29	8070-8073	and	_
58-30	8074-8085	personality	_
58-31	8086-8087	(	_
58-32	8088-8092	SVM3	_
58-33	8093-8094	)	_
58-34	8095-8096	.	_

59-1	8097-8101	Each	_
59-2	8102-8104	of	_
59-3	8105-8110	these	_
59-4	8111-8115	SVMs	_
59-5	8116-8119	was	_
59-6	8120-8127	trained	_
59-7	8128-8133	using	_
59-8	8134-8137	the	_
59-9	8138-8141	LOO	_
59-10	8142-8151	procedure	_
59-11	8152-8154	on	_
59-12	8155-8158	the	_
59-13	8159-8167	training	_
59-14	8168-8172	data	_
59-15	8173-8174	,	_
59-16	8175-8184	including	_
59-17	8185-8188	the	_
59-18	8189-8196	Control	_
59-19	8197-8198	I	_
59-20	8199-8204	group	_
59-21	8205-8206	,	_
59-22	8207-8210	the	_
59-23	8211-8220	long-term	_
59-24	8221-8226	binge	_
59-25	8227-8235	drinking	_
59-26	8236-8241	group	_
59-27	8242-8243	,	_
59-28	8244-8247	and	_
59-29	8248-8251	the	_
59-30	8252-8262	short-term	_
59-31	8263-8268	binge	_
59-32	8269-8277	drinking	_
59-33	8278-8283	group	_
59-34	8284-8285	.	_

60-1	8286-8288	In	_
60-2	8289-8292	the	_
60-3	8293-8302	out-layer	_
60-4	8303-8304	,	_
60-5	8305-8308	one	_
60-6	8309-8312	SVM	_
60-7	8313-8314	(	_
60-8	8315-8319	SVM4	_
60-9	8320-8321	)	_
60-10	8322-8330	received	_
60-11	8331-8335	only	_
60-12	8336-8337	3	_
60-13	8338-8343	input	_
60-14	8344-8350	values	_
60-15	8351-8355	from	_
60-16	8356-8359	the	_
60-17	8360-8366	output	_
60-18	8367-8373	values	_
60-19	8374-8376	of	_
60-20	8377-8383	SVM1–3	_
60-21	8384-8385	(	_
60-22	8386-8387	a	_
60-23	8388-8395	greater	_
60-24	8396-8402	output	_
60-25	8403-8408	value	_
60-26	8409-8414	means	_
60-27	8415-8419	more	_
60-28	8420-8426	likely	_
60-29	8427-8429	to	_
60-30	8430-8432	be	_
60-31	8433-8434	a	_
60-32	8435-8440	binge	_
60-33	8441-8448	drinker	_
60-34	8449-8450	)	_
60-35	8451-8452	.	_

61-1	8453-8457	With	_
61-2	8458-8462	this	_
61-3	8463-8475	hierarchical	_
61-4	8476-8486	classifier	_
61-5	8487-8488	,	_
61-6	8489-8491	we	_
61-7	8492-8505	significantly	_
61-8	8506-8513	reduced	_
61-9	8514-8517	the	_
61-10	8518-8523	model	_
61-11	8524-8534	complexity	_
61-12	8535-8537	by	_
61-13	8538-8544	taking	_
61-14	8545-8548	the	_
61-15	8549-8555	inputs	_
61-16	8556-8560	from	_
61-17	8561-8566	three	_
61-18	8567-8572	kinds	_
61-19	8573-8575	of	_
61-20	8576-8584	features	_
61-21	8585-8586	,	_
61-22	8587-8589	so	_
61-23	8590-8592	as	_
61-24	8593-8595	to	_
61-25	8596-8603	achieve	_
61-26	8604-8605	a	_
61-27	8606-8612	better	_
61-28	8613-8629	generalizability	_
61-29	8630-8631	.	_

62-1	8632-8635	The	_
62-2	8636-8641	model	_
62-3	8642-8645	was	_
62-4	8646-8650	then	_
62-5	8651-8657	tested	_
62-6	8658-8663	using	_
62-7	8664-8666	an	_
62-8	8667-8678	independent	_
62-9	8679-8683	test	_
62-10	8684-8690	sample	_
62-11	8691-8692	(	_
62-12	8693-8696	i.e	_
62-13	8697-8698	.	_

63-1	8699-8702	the	_
63-2	8703-8714	medium-term	_
63-3	8715-8723	drinkers	_
63-4	8724-8727	and	_
63-5	8728-8731	the	_
63-6	8732-8739	Control	_
63-7	8740-8742	II	http://maven.renci.org/NeuroBridge/neurobridge#II
63-8	8743-8748	group	_
63-9	8749-8750	)	_
63-10	8751-8752	.	_

64-1	8753-8765	Longitudinal	_
64-2	8766-8774	analysis	_
64-3	8775-8777	We	_
64-4	8778-8783	could	_
64-5	8784-8787	not	_
64-6	8788-8795	conduct	_
64-7	8796-8797	a	_
64-8	8798-8810	longitudinal	_
64-9	8811-8819	analysis	_
64-10	8820-8822	on	_
64-11	8823-8826	the	_
64-12	8827-8833	rsfMRI	_
64-13	8834-8838	data	_
64-14	8839-8846	because	_
64-15	8847-8849	we	_
64-16	8850-8854	only	_
64-17	8855-8858	had	_
64-18	8859-8861	32	_
64-19	8862-8870	subjects	_
64-20	8871-8872	(	_
64-21	8873-8875	18	_
64-22	8876-8881	binge	http://maven.renci.org/NeuroBridge/neurobridge#DrinkingBinge
64-23	8882-8890	drinkers	_
64-24	8891-8894	and	_
64-25	8895-8897	14	_
64-26	8898-8906	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
64-27	8907-8908	)	_
64-28	8909-8913	with	_
64-29	8914-8920	rsfMRI	_
64-30	8921-8925	data	_
64-31	8926-8935	available	_
64-32	8936-8938	at	_
64-33	8939-8942	the	_
64-34	8943-8946	age	_
64-35	8947-8949	of	_
64-36	8950-8952	14	_
64-37	8953-8958	after	_
64-38	8959-8970	participant	_
64-39	8971-8980	selection	_
64-40	8981-8982	(	_
64-41	8983-8987	eFig	_
64-42	8988-8989	.	_

65-1	8990-8991	1	_
65-2	8992-8993	)	_
65-3	8994-8995	.	_

66-1	8996-9003	However	_
66-2	9004-9005	,	_
66-3	9006-9019	personalities	_
66-4	9020-9024	were	_
66-5	9025-9033	assessed	_
66-6	9034-9036	at	_
66-7	9037-9042	three	_
66-8	9043-9047	time	_
66-9	9048-9054	points	_
66-10	9055-9056	(	_
66-11	9057-9061	ages	_
66-12	9062-9064	14	_
66-13	9065-9066	,	_
66-14	9067-9069	16	_
66-15	9070-9071	,	_
66-16	9072-9075	and	_
66-17	9076-9078	19	_
66-18	9079-9080	)	_
66-19	9081-9082	;	_
66-20	9083-9092	therefore	_
66-21	9093-9094	,	_
66-22	9095-9097	we	_
66-23	9098-9107	estimated	_
66-24	9108-9115	changes	_
66-25	9116-9118	in	_
66-26	9119-9130	personality	_
66-27	9131-9138	between	_
66-28	9139-9141	14	_
66-29	9142-9145	and	_
66-30	9146-9148	16	_
66-31	9149-9154	years	_
66-32	9155-9156	(	_
66-33	9157-9172	difference16–14	_
66-34	9173-9174	)	_
66-35	9175-9178	and	_
66-36	9179-9186	between	_
66-37	9187-9189	16	_
66-38	9190-9193	and	_
66-39	9194-9196	19	_
66-40	9197-9202	years	_
66-41	9203-9204	(	_
66-42	9205-9220	difference19–16	_
66-43	9221-9222	)	_
66-44	9223-9224	.	_

67-1	9225-9227	To	_
67-2	9228-9235	compare	_
67-3	9236-9239	the	_
67-4	9240-9253	developmental	_
67-5	9254-9264	trajectory	_
67-6	9265-9267	of	_
67-7	9268-9279	personality	_
67-8	9280-9287	between	_
67-9	9288-9291	the	_
67-10	9292-9295	two	_
67-11	9296-9305	different	_
67-12	9306-9310	time	_
67-13	9311-9318	periods	_
67-14	9319-9320	(	_
67-15	9321-9324	i.e	_
67-16	9325-9326	.	_

68-1	9327-9331	from	_
68-2	9332-9334	14	_
68-3	9335-9337	to	_
68-4	9338-9340	16	_
68-5	9341-9344	and	_
68-6	9345-9349	from	_
68-7	9350-9352	16	_
68-8	9353-9355	to	_
68-9	9356-9358	19	_
68-10	9359-9360	)	_
68-11	9361-9362	,	_
68-12	9363-9378	difference16–14	_
68-13	9379-9382	and	_
68-14	9383-9398	difference19–16	_
68-15	9399-9401	in	_
68-16	9402-9407	binge	_
68-17	9408-9416	drinkers	_
68-18	9417-9421	must	_
68-19	9422-9424	be	_
68-20	9425-9436	established	_
68-21	9437-9443	before	_
68-22	9444-9447	and	_
68-23	9448-9453	after	_
68-24	9454-9459	binge	_
68-25	9460-9468	drinking	_
68-26	9469-9474	onset	_
68-27	9475-9476	,	_
68-28	9477-9489	respectively	_
68-29	9490-9491	,	_
68-30	9492-9496	thus	_
68-31	9497-9501	only	_
68-32	9502-9505	the	_
68-33	9506-9516	short-term	_
68-34	9517-9525	drinkers	_
68-35	9526-9535	satisfied	_
68-36	9536-9540	this	_
68-37	9541-9550	condition	_
68-38	9551-9552	.	_

69-1	9553-9558	These	_
69-2	9559-9570	differences	_
69-3	9571-9575	were	_
69-4	9576-9584	compared	_
69-5	9585-9591	before	_
69-6	9592-9595	and	_
69-7	9596-9601	after	_
69-8	9602-9605	the	_
69-9	9606-9611	onset	_
69-10	9612-9614	of	_
69-11	9615-9620	binge	_
69-12	9621-9629	drinking	_
69-13	9630-9631	(	_
69-14	9632-9644	significance	_
69-15	9645-9648	was	_
69-16	9649-9654	given	_
69-17	9655-9657	by	_
69-18	9658-9662	1000	_
69-19	9663-9675	permutations	_
69-20	9676-9678	of	_
69-21	9679-9682	the	_
69-22	9683-9689	paired	_
69-23	9690-9696	median	_
69-24	9697-9701	test	_
69-25	9702-9703	)	_
69-26	9704-9705	.	_

70-1	9706-9708	By	_
70-2	9709-9719	conducting	_
70-3	9720-9722	an	_
70-4	9723-9731	Analysis	_
70-5	9732-9734	of	_
70-6	9735-9743	Variance	_
70-7	9744-9745	(	_
70-8	9746-9751	ANOVA	_
70-9	9752-9753	)	_
70-10	9754-9758	with	_
70-11	9759-9767	repeated	_
70-12	9768-9776	measures	_
70-13	9777-9782	using	_
70-14	9783-9787	SPSS	_
70-15	9788-9789	(	_
70-16	9790-9798	Released	_
70-17	9799-9803	2011	_
70-18	9804-9805	.	_

71-1	9806-9809	IBM	_
71-2	9810-9814	SPSS	_
71-3	9815-9825	Statistics	_
71-4	9826-9829	for	_
71-5	9830-9837	Windows	_
71-6	9838-9839	,	_
71-7	9840-9847	Version	_
71-8	9848-9852	20.0	_
71-9	9853-9854	.	_

72-1	9855-9861	Armonk	_
72-2	9862-9863	,	_
72-3	9864-9866	NY	_
72-4	9867-9868	:	_
72-5	9869-9872	IBM	_
72-6	9873-9877	Corp	_
72-7	9878-9879	)	_
72-8	9880-9881	,	_
72-9	9882-9884	we	_
72-10	9885-9889	were	_
72-11	9890-9894	able	_
72-12	9895-9897	to	_
72-13	9898-9905	compare	_
72-14	9906-9909	the	_
72-15	9910-9922	longitudinal	_
72-16	9923-9933	evolutions	_
72-17	9934-9936	of	_
72-18	9937-9941	both	_
72-19	9942-9945	the	_
72-20	9946-9957	impulsivity	_
72-21	9958-9961	and	_
72-22	9962-9965	the	_
72-23	9966-9983	sensation-seeking	_
72-24	9984-9990	scores	_
72-25	9991-9998	between	_
72-26	9999-10002	the	_
72-27	10003-10013	short-term	_
72-28	10014-10022	drinkers	_
72-29	10023-10026	and	_
72-30	10027-10030	the	_
72-31	10031-10038	control	_
72-32	10039-10047	subjects	_
72-33	10048-10049	.	_

73-1	10050-10053	The	_
73-2	10054-10058	same	_
73-3	10059-10067	approach	_
73-4	10068-10071	was	_
73-5	10072-10076	also	_
73-6	10077-10084	applied	_
73-7	10085-10087	to	_
73-8	10088-10103	difference16–14	_
73-9	10104-10107	and	_
73-10	10108-10123	difference19–16	_
73-11	10124-10125	.	_

74-1	10126-10129	The	_
74-2	10130-10140	covariates	_
74-3	10141-10142	(	_
74-4	10143-10146	sex	_
74-5	10147-10150	and	_
74-6	10151-10155	data	_
74-7	10156-10166	collection	_
74-8	10167-10172	sites	_
74-9	10173-10174	)	_
74-10	10175-10179	were	_
74-11	10180-10190	regressing	_
74-12	10191-10194	out	_
74-13	10195-10199	from	_
74-14	10200-10203	the	_
74-15	10204-10216	measurements	_
74-16	10217-10223	before	_
74-17	10224-10227	the	_
74-18	10228-10233	group	_
74-19	10234-10245	comparisons	_
74-20	10246-10247	.	_

